Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2024 04:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu...
November 15, 2024 16:00 ET | Source: INVENTIVA

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...
November 14, 2024 16:15 ET | Source: California BanCorp

California Bank of Commerce Names Jerry Legg Director of Public Sector Banking

San Diego, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- California Bank of Commerce, N.A. (the “Bank”), the wholly owned subsidiary of California BanCorp (Nasdaq: BCAL), announces the appointment of...
November 05, 2024 23:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the...
October 30, 2024 16:00 ET | Source: INVENTIVA

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on...
October 21, 2024 08:30 ET | Source: INVENTIVA

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company...
October 17, 2024 09:43 ET | Source: First Responders Children's Foundation

First Responders Children’s Foundation Announces 2024 CSX Pride in Service Scholarship Recipients

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- First Responders Children’s Foundation (FRCF), a national 501(c)3 organization dedicated to serving the children of U.S. first responders including...
October 16, 2024 00:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who...
October 15, 2024 11:45 ET | Source: LVMH

LVMH shows good resilience in the current context

Paris, October 15, 2024 LVMH Moët Hennessy Louis Vuitton, the world’s leading high-quality products group, recorded revenue of €60.8 billion in the first nine months of 2024, stable...
October 14, 2024 13:45 ET | Source: INVENTIVA

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company...